Citations (7)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Marjan Massoudi, Mark Balk, Hongbo Yang, Cat N. Bui, Bhavik J. Pandya, Jenny Guo, Yan Song, Eric Q. Wu, Bruce Brown, Arie Barlev & Scott Flanders. (2017) Number needed to treat and associated incremental costs of treatment with enzalutamide versus abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer. Journal of Medical Economics 20:2, pages 121-128.
Read now
Read now
Articles from other publishers (6)
Daniel M Geynisman, Ella X Du, Xiaoran Yang, Selvam R Sendhil, Viviana Del Tejo, Keith A Betts & Stephen Huo. (2022) Temporal trends of adverse events and costs of nivolumab plus ipilimumab versus sunitinib in advanced renal cell carcinoma. Future Oncology 18:10, pages 1219-1234.
Crossref
Crossref
Anuja ChatterjeeSheila ShapouriBeenish S ManzoorArliene RaveloKavita SailVenetia QendriGijs van de WeteringMatthew S Davids. (2021) Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United States. Journal of Managed Care & Specialty Pharmacy 27:11, pages 1532-1544.
Crossref
Crossref
Abhijeet Bhanegaonkar, Shivani Pandya, Ying Zheng, Ruth Kim, Stan Krulewicz, Vijay Kasturi & Hemant Phatak. (2021) Real-World Outcomes Among US Veterans Health Administration Patients Newly Diagnosed with Metastatic Renal Cell Carcinoma and Treated with First-Line Monotherapy. Advances in Therapy 38:5, pages 2644-2661.
Crossref
Crossref
Gregory A. Joice, Meera R. Chappidi, Hiten D. Patel, Max Kates, Nikolai A. Sopko, C. J. Stimson, Phillip M. Pierorazio & Trinity J. Bivalacqua. (2018) Hospitalisation and readmission costs after radical cystectomy in a nationally representative sample: does urinary reconstruction matter?. BJU International 122:6, pages 1016-1024.
Crossref
Crossref
Julie M. Bullock, Tiffany Lin & Sanela Bilic. (2017) Clinical Pharmacology Tools and Evaluations to Facilitate Comprehensive Dose Finding in Oncology: A Continuous Risk-Benefit Approach. The Journal of Clinical Pharmacology 57, pages S105-S115.
Crossref
Crossref
Meera R. Chappidi, Max Kates, C.J. Stimson, Michael H. Johnson, Phillip M. Pierorazio & Trinity J. Bivalacqua. (2017) Causes, Timing, Hospital Costs and Perioperative Outcomes of Index vs Nonindex Hospital Readmissions after Radical Cystectomy: Implications for Regionalization of Care. Journal of Urology 197:2, pages 296-301.
Crossref
Crossref